Anaplastic Large Cell Lymphoma Completed Phase 1 Trials for Bortezomib (DB00188)

Also known as: Lymphomas, Anaplastic Large-Cell / Anaplastic large-cell lymphoma / Large cell (Ki-1+) lymphoma / Lymphoma, Large-Cell, Anaplastic / Anaplastic large cell lymphoma, CD30-positive

IndicationStatusPhase
DBCOND0028602 (Anaplastic Large Cell Lymphoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00348985PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTreatment
NCT01129180Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell LymphomaTreatment